Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

Summary Background A substantial proportion of patients with type 2 diabetes are elderly (≥65 years) but this group has been largely excluded from clinical studies of glucose-lowering drugs. We aimed to assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2013-10, Vol.382 (9902), p.1413-1423
Hauptverfasser:	Barnett, Anthony H, Prof, Huisman, Holger, MSc, Jones, Russell, MSc, von Eynatten, Maximilian, MD, Patel, Sanjay, MB ChB, Woerle, Hans-Juergen, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Analysis of Variance Biological and medical sciences Blood Glucose - drug effects Clinical trials Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Double-Blind Method Drug dosages elderly Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Gastrointestinal surgery General aspects Glucose Glycated Hemoglobin A - drug effects Heart attacks hemoglobin Humans hypoglycemia Hypoglycemic Agents - therapeutic use Infections Insulin Internal Medicine Linagliptin Male Medical sciences metformin noninsulin-dependent diabetes mellitus odds ratio oral administration patients Purines - therapeutic use Quinazolines - therapeutic use risk sulfonylureas Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background A substantial proportion of patients with type 2 diabetes are elderly (≥65 years) but this group has been largely excluded from clinical studies of glucose-lowering drugs. We aimed to assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients with type 2 diabetes. Methods In this randomised, double-blind, parallel-group, multinational phase 3 study, patients aged 70 years or older with type 2 diabetes, glycated haemoglobin A1c (HbA1c ) of 7·0% or more, receiving metformin, sulfonylureas, or basal insulin, or combinations of these drugs, were randomised (by computer-generated randomisation sequence, concealed with a voice–response system, stratified by HbA1c level [
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(13)61500-7